.png){kind=icon}
.png){kind=icon}
Return
PIKfyve-specific Pt(II)-based targeted drug conjugate in treatment of ovarian cancer through multi-mode actions
.png){kind=icon}
PRE
AI
H
G
S
DOI：10.1016/j.jinorgbio.2026.113398.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• AP-604 overcomes platinum resistance in ovarian cancer. • AP-604 retains nanomolar PIKfyve affinity and potent cytotoxicity. • AP-604 enhances platinum accumulation and DNA platination. • AP-604 induces S phase arrest and BCL-2/caspase apoptosis. • AP-604 shows superior in vivo efficacy with low systemic toxicity.
Journal
IF:
3.2
Papers:
7.1K
Citations:
1.2W
Organization
No organization information available
Cited Papers